The DOI matches its Crossref record; 108 of the 118 references it cites were found in a registry or an index.
TP53 mutations in human cancers: origins, consequences, and clinical use.
Open accessAbstract
Somatic mutations in the TP53 gene are one of the most frequent alterations in human cancers, and germline mutations are the underlying cause of Li-Fraumeni syndrome, which predisposes to a wide spectrum of early-onset cancers. Most mutations are single-base substitutions distributed throughout the coding sequence. Their diverse types and positions may inform on the nature of mutagenic mechanisms involved in cancer etiology. TP53 mutations are also potential prognostic and predictive markers, as well as targets for pharmacological intervention. All mutations found in human cancers are compiled in the IARC TP53 Database (http://www-p53.iarc.fr/). A human TP53 knockin mouse model (Hupki mouse) provides an experimental model to study mutagenesis in the context of a human TP53 sequence. Here, we summarize current knowledge on TP53 gene variations observed in human cancers and populations, and current clinical applications derived from this knowledge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, 38-50% of human cancers carry inactivating alterations in TP53 (ref. 132 ) , 48-80% in CDKN2A 133 and 14% in CIP1 (ref. 134 ) , while 15-20% and up to 8% harbour oncogenic mutations in RAS and BRAF , respectively 135,136 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [132]
Experimental — accuracy not yet measuredIn the citing paper
“Activated p53 regulates expression of a set of anti-proliferative genes (Olivier et al., 2010; Kastenhuber and Lowe, 2017).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Olivier et al., 2010
In the citing paper
“As p53 remains wild type in $50% of human cancers, 6 reactivation of p53 by small molecules is an attractive therapeutic approach.”
From Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death (2013) · cites this paper as [6]
In the citing paper
“Tumors, which drastically deviate from these parameters, have evolved multiple mechanisms to inactivate TP53, the most prevalent of which is the emergence of TP53 missense mutations, some of which have gain-of function activities.”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Olivier, et al., 2010
In the citing paper
“In particular, missense mutations account for approximately 75% of all TP53 mutations in cancer (Hamroun, et al., 2006; Olivier, et al., 2010)”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Olivier, et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Self-citationp53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,625
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559 · cited 2×
“The p53 DBD is made of an immunoglobulinlike b-sandwich of two antiparallel b-sheets, providing a scaffold for a flexible DNA-binding surface (Cho et al. 1994).”
BackgroundCrypt stem cells as the cells-of-origin of intestinal cancer
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., & Clevers, H. C. (2008) · Nature · doi:10.1038/nature07602 · Cited by 2,232
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
Preferential Formation of Benzo[ a ]pyrene Adducts at Lung Cancer Mutational Hotspots in P53
Denissenko, M. F., Pao, A., Tang, M.-S., & Pfeifer, G. P. (1996) · Science · doi:10.1126/science.274.5286.430 · Cited by 1,650
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 8×
“Data from IARC TP53 Database (R13, November 2008)(Petitjean et al. 2007b).”
BackgroundMethodInfluentialSelf-citationMutational hot spot in the p53 gene in human hepatocellular carcinomas
Hsu, I., Metcalf, R. A., Sun, T., Welsh, J. A., Wang, N. J., & Harris, C. C. (1991) · Nature · doi:10.1038/350427a0 · Cited by 1,533
Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa
Paillerets, B. B., Kew, M. C., Wands, J. R., & Öztürk, M. (1991) · Nature · doi:10.1038/350429a0 · Cited by 1,433
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
A cancer family syndrome in twenty-four kindreds.
Li, F. P., Fraumeni, J. F., Mulvihill, J. J., Blattner, W. A., Dreyfus, M., Tucker, M., & Miller, R. (1988) · PubMed · Cited by 1,293
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
Oda, K., Arakawa, H., Tanaka, T., Matsuda, K., Tanikawa, C., Mori, T., Nishimori, H., Tamai, K., Tokino, T., Nakamura, Y., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00073-8 · Cited by 1,162
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers
Pfeifer, G. P., Denissenko, M. F., Olivier, M., Tretyakova, N. Y., Hecht, S. S., & Hainaut, P. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205803 · Cited by 1,107
Self-citationGain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
p53 and Human Cancer: The First Ten Thousand Mutations
Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 999
Self-citationRole of a p53 polymorphism in the development of human papilloma-virus-associated cancer
Storey, A., Thomas, M., Kalita, A., Harwood, C. A., Gardiol, D., Mantovani, F., Breuer, J., Leigh, I. M., Matlashewski, G., & Banks, L. (1998) · Nature · doi:10.1038/30400 · Cited by 971
Modelling the molecular circuitry of cancer
Hahn, W. C., & Weinberg, R. A. (2002) · Nature reviews. Cancer · doi:10.1038/nrc795 · Cited by 953
Kato, S., Han, S., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., & Ishioka, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1431692100 · Cited by 895
TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes
Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884
Self-citationMutant p53 Gain-of-Function in CancerPreprint
Oren, M., & Rotter, V. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001107 · Cited by 778
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P. M., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M. G., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 760
Aas, T., Børresen‐Dale, A., Geisler, S. B., Smith‐Sørensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., & Lønning, P. E. (1996) · Nature Medicine · doi:10.1038/nm0796-811 · Cited by 736
p53 polymorphisms: cancer implications
Whibley, C., Pharoah, P. D. P., & Hollstein, M. C. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2584 · Cited by 677
Self-citationHussain, S. P., Schwank, J., Staib, F., Wang, X. W., & Harris, C. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210279 · Cited by 643
Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations
Hagman, K. D. F., Noltner, K., Buzin, C. H., Gu, D., Wen, C. Y., Nguyen, V. Q., Han, J., Lowstuter, K. J., Longmate, J., Sommer, S. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6959 · Cited by 607
Aristolochic acid and the etiology of endemic (Balkan) nephropathy
Grollman, A. P., Shibutani, S., Moriya, M., Miller, F. W., Wu, L., Moll, U. M., Suzuki, N., Fernandes, A., Rosenquist, T. A., Medverec, Z., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701248104 · Cited by 603
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier, M., Langer√∏d, A., Carrieri, P., Bergh, J. C. S., Klaar, S., Eyfjord, J. E., Theillet, C. G., Rodríguez, C., Lidereau, R., Bièche, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1029 · Cited by 590
Self-citationA common polymorphism acts as an intragenic modifier of mutant p53 behaviour
Marín, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O’Nions, J., TIDY, J. A., James, N. D., McGregor, J., Harwood, C. A., Yuluğ, I. G., et al. (2000) · Nature Genetics · doi:10.1038/75586 · Cited by 511
Olivier, M., Goldgar, D. E., Sodha, N., Ohgaki, H., Kleihues, P., Hainaut, P. L., & Eeles, R. A. (2003) · PubMed · Cited by 480
Self-citationRelative frequency and morphology of cancers in carriers of germline TP53 mutations
Birch, J. M., Alston, R. D., McNally, R. J., Evans, D. G. R., Kelsey, A. M., Harris, M., Eden, O. B., & Varley, J. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204621 · Cited by 467
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM
Song, H., Hollstein, M., & Xu, Y. (2007) · Nature Cell Biology · doi:10.1038/ncb1571 · Cited by 456
Self-citationBergh, J. C. S., Norberg, T., Sjögren, S., Lindgren, A., & Holmberg, L. (1995) · Nature Medicine · doi:10.1038/nm1095-1029 · Cited by 456
Bergamaschi, D., Gasco, M., Hiller, L., Sullivan, A., Syed, N., Trigiante, G., Yuluğ, I. G., Merlano, M. C., Numico, G., Comino, A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00079-5 · Cited by 445
Structure–function–rescue: the diverse nature of common p53 cancer mutants
Joerger, A. C., & Fersht, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210291 · Cited by 442
Bullock, A. N., Henckel, J., & Fersht, A. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203434 · Cited by 440
Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., & Levine, A. J. (1990) · PubMed · Cited by 408
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 398
Structural basis for understanding oncogenic p53 mutations and designing rescue drugs
Joerger, A. C., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607286103 · Cited by 368
Stephens, P., Edkins, S., Davies, H. R., Greenman, C., Cox, C., Hunter, C., Bignell, G. R., Teague, J. W., Smith, R., Stevens, C., et al. (2005) · Nature Genetics · doi:10.1038/ng1571 · Cited by 333
Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis.
Franklin, W. A., Gazdar, A. F., Haney, J. C., Wistuba, I. I., Rosa, F. G. L., Kennedy, T., Ritchey, D. M., & Miller, Y. E. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119748 · Cited by 331
TP53 mutations in human skin cancers
Giglia‐Mari, G., & Sarasin, A. R. (2003) · Human Mutation · doi:10.1002/humu.10179 · Cited by 298
TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer
Langerød, A., Zhao, H., Borgan, Ø., Nesland, J. M., Bukholm, I. R., Ikdahl, T., Kåresen, R., Børresen‐Dale, A., & Jeffrey, S. S. (2007) · Breast Cancer Research · doi:10.1186/bcr1675 · Cited by 295
Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs
Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 247
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer.
Olivier, M., Hussain, S. P., de Fromentel, C. C., Hainaut, P. L., & Harris, C. C. (2004) · PubMed · Cited by 243
Self-citationScreening patients for heterozygous p53 mutations using a functional assay in yeast
Ishioka, C., Frébourg, T., Yan, Y.-X., Vidal, M., Friend, S. H., Schmidt, S., & Iggo, R. D. (1993) · Nature Genetics · doi:10.1038/ng1093-124 · Cited by 243
Gemignani, F., Moreno, V. R., Landi, S., Moullan, N., Chabrier, A., Gutiérrez‐Enríquez, S., Hall, J. A., Guinó, E., Peinado, M. A., Capellá, G., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1207305 · Cited by 217
Bougeard, G., Baert-Desurmont, S., Tournier, I., Vasseur, S., Martin, C., Brugières, L., Chompret, A., Paillerets, B. B., Stoppa‐Lyonnet, D., Bonaïti‐Pellié, C., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.037952 · Cited by 216
Germline mutations in the TP53 gene.
Eeles, R. A. (1995) · PubMed · Cited by 213
Characterization of genome-wide p53-binding sites upon stress response
Smeenk, L., van Heeringen, S. J., Koeppel, M., van Driel, M. A., Bartels, S. J. J., Akkers, R. C., Denissov, S., Stunnenberg, H. G., & Lohrum, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn232 · Cited by 211
The role of TP53 in Cervical carcinogenesis
Tommasino, M., Accardi, R., Caldeira, S., Dong, W., Malanchi, I., Smet, A., & Zehbe, I. (2003) · Human Mutation · doi:10.1002/humu.10178 · Cited by 207
Methylation, mutation and cancer
Jones, P. A., Rideout, W. M., Shen, J., Spruck, C., & Tsai, Y. (1992) · BioEssays · doi:10.1002/bies.950140107 · Cited by 205
Langerød, A., Bukholm, I., Bregård, A., Lønning, P. E., Andersen, T. I., Rognum, T. O., Meling, G. I., Lothe, R. A., & Børresen‐Dale, A. (2002) · PubMed · Cited by 204
Inga, A., Storici, F., Darden, T. A., & Resnick, M. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.24.8612-8625.2002 · Cited by 195
Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans
Kang, H.-J., Feng, Z., Sun, Y., Atwal, G., Murphy, M. E., Rebbeck, T. R., Rosenwaks, Z., Levine, A. J., & Hu, W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904280106 · Cited by 193
Ser-249 p53 Mutations in Plasma DNA of Patients With Hepatocellular Carcinoma From The Gambia
Kirk, G. D., Camus-Randon, A.-M., Mendy, M. E., Goedert, J. J., Merle, P., TREPO, C. G., Bréchot, C., Hainaut, P. L., & Montesano, R. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.2.148 · Cited by 190
Self-citationStructures of p53 Cancer Mutants and Mechanism of Rescue by Second-site Suppressor Mutations
Joerger, A. C., Ang, H. C., Veprintsev, D. B., Blair, C. M., & Fersht, A. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500179200 · Cited by 181
Mutational spectra of human cancer
Pfeifer, G. P., & Nia, A. B. (2009) · Human Genetics · doi:10.1007/s00439-009-0657-2 · Cited by 180
BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives
Lalloo, F. I., Varley, J. M., Moran, A., Ellis, D., O’Dair, L., Pharoah, P. D. P., Antoniou, A. C., Hartley, R., Shenton, A., Seal, S., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.032 · Cited by 175
Arlt, V. M., Stiborová, M., Brocke, J. V., Simões, M. L., Lord, G. M., Nortier, J., Hollstein, M., Phillips, D. H., & Schmeiser, H. H. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm082 · Cited by 173
Self-citationBonafè, M., Ceccarelli, C., Farabegoli, F., Santini, D., Taffurelli, M., Barbi, C., Marzi, E., Trapassi, C., Storci, G., Olivieri, F., et al. (2003) · PubMed · Cited by 171
Dominant-negative p53 mutations selected in yeast hit cancer hot spots.
Brachmann, R. K., Vidal, M., & Boeke, J. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4091 · Cited by 162
TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis
Matakidou, A. (2003) · Mutagenesis · doi:10.1093/mutage/geg008 · Cited by 150
Luo, J., Yang, Q., Tong, W., Hergenhahn, M., Wang, Z., & Hollstein, M. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204080 · Cited by 135
Self-citationSer46 Phosphorylation Regulates p53-Dependent Apoptosis and Replicative Senescence
Feng, L., Hollstein, M., & Xu, Y. (2006) · Cell Cycle · doi:10.4161/cc.5.23.3526 · Cited by 119
Self-citationTP53 Status and Response to Chemotherapy in Breast Cancer
Bertheau, P., Espié, M., Turpin, E., Lehmann‐Che, J., Plassa, L., Varna, M., Janin, A., & de Thé, H. (2008) · Pathobiology · doi:10.1159/000123851 · Cited by 111
Molecular pathology in basal cell cancer with p53 as a genetic marker
Pontén, F., Berg, C., Ahmadian, A., Ren, Z.-P., Nistér, M., Lundeberg, J., Uhlén, M., & Pontén, J. (1997) · Oncogene · doi:10.1038/sj.onc.1201435 · Cited by 110
Jia, L., Liu, Y., Yi, X., Miron, A., Crum, C. P., Kong, B., & Zheng, W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4837 · Cited by 110
Shi, H., Tan, S.-J., Zhong, H., Hu, W., Levine, A. J., Xiao, C.-J., Peng, Y., Qi, X.-B., Shou, W., Run-lin, Z., et al. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.03.009 · Cited by 108
Single-nucleotide Polymorphisms in the p53 Signaling PathwayPreprint
Grochola, L. F., Zeron-Medina, J., Meriaux, S., & Bond, G. L. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001032 · Cited by 105
Functional studies of a germ-line polymorphism at codon 47 within the p53 gene.
Felley‐Bosco, E., Weston, A., Cawley, H., Bennett, W. P., & Harris, C. C. (1993) · Europe PMC (PubMed Central) · Cited by 103
Mechanisms for the involvement of DNA methylation in colon carcinogenesis.
Schmütte, C., Yang, A. S., Nguyen, T. T., Beart, R. W., & Jones, P. A. (1996) · PubMed · Cited by 103
Liu, Z., Hergenhahn, M., Schmeiser, H. H., Wogan, G. N., Hong, A., & Hollstein, M. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308607101 · Cited by 95
Self-citationOn the origin of G→T transversions in lung cancer
Pfeifer, G. P., & Hainaut, P. L. (2003) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(03)00013-7 · Cited by 86
Self-citationp53 germline polymorphisms are associated with an increased risk for breast cancer in German women.
Wang‐Gohrke, S., Rebbeck, T. R., Besenfelder, W., Kreienberg, R., & Runnebaum, I. B. (1998) · PubMed · Cited by 84
de Fromentel, C. C., Gruel, N., Venot, C., Debüssche, L., Conseiller, E., Dureuil, C., Teillaud, J., Tocqué, B., & Bracco, L. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202338 · Cited by 83
Nedelko, T., Arlt, V. M., Phillips, D. H., & Hollstein, M. C. (2008) · International Journal of Cancer · doi:10.1002/ijc.24006 · Cited by 82
Self-citationBougeard, G., Brugières, L., Chompret, A., Gesta, P., Charbonnier, F., Valent, A., Martin, C., Raux, G., Feunteun, J., Paillerets, B. B., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206155 · Cited by 82
Schmidt, M. K., Reincke, S., Broeks, A., Braaf, L. M., Hogervorst, F. B. L., Tollenaar, R. A. �. �., Johnson, N., Fletcher, O., Peto, J., Tommiska, J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0738 · Cited by 79
Marcel, V., Palmero, E. I., Falagan-Lotsch, P., Martel‐Planche, G., Ashton‐Prolla, P., Olivier, M., Brentani, H., Hainaut, P. L., & Achatz, M. I. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2009.066704 · Cited by 78
Self-citationVikhanskaya, F., Siddique, M. M., Lee, M. K., Broggini, M., & Sabapathy, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1547 · Cited by 75
TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
Wang, Y., Helland, Å., Holm, R., Skomedal, H., Abeler, V. M., Danielsen, H. E., Tropé, C., Børresen-Dale, A.-L., & Kristensen, G. B. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601537 · Cited by 68
Wang‐Gohrke, S., Weikel, W., Risch, H. A., Vesprini, D., Abrahamson, J., Lerman, C., Godwin, A. K., Moslehi, R., Olipade, O., Brunet, J., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690669 · Cited by 67
TP53 mutation, allelism and survival in non-small cell lung cancer
Nelson, H. H., Wilkojmen, M., Marsit, C. J., & Kelsey, K. T. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi125 · Cited by 66
A functional screen for germ line p53 mutations based on transcriptional activation.
Frébourg, T., Barbier, N., Kassel, J., Ng, Y. S., Beer‐Romero, P., & Friend, S. H. (1992) · PubMed · Cited by 64
Beyond Li-Fraumeni syndrome: Clinical characteristics of families with p53 germline mutations
Gonzalez, K. D., Noltner, K., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Ngyuen, V. Q., Han, J. H., Lowstuter, K., Longmate, J., Sommer, S. S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.11031 · Cited by 58
TP53 polymorphism, HPV infection, and risk of cervical cancer.
Klug, S. J., Wilmotte, R., Santos, C., Almonte, M., Herrero, R., Guerrero, I., Caceres, E., Guimarães, D. P., Lenoir, G., Hainaut, P. L., et al. (2001) · PubMed · Cited by 55
Self-citationVaninetti, N. M., Geldenhuys, L., Porter, G. A., Risch, H. A., Hainaut, P. L., Guernsey, D. L., & Casson, A. G. (2007) · Molecular Carcinogenesis · doi:10.1002/mc.20382 · Cited by 54
Self-citationWang, Y., Kringen, P., Kristensen, G. B., Holm, R., Baekelandt, M. M. O., Olivier, M., Skomedal, H., Hainaut, P. L., Trope, C. G., Abeler, V. M., et al. (2004) · Human Mutation · doi:10.1002/humu.20055 · Cited by 52
Self-citationMEF immortalization to investigate the ins and outs of mutagenesis
Brocke, J. V., Schmeiser, H. H., Reinbold, M., & Hollstein, M. C. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl101 · Cited by 51
Self-citationA review of contusugene ladenovec (Advexin) p53 therapy.
Senzer, N. N., & Nemunaitis, J. J. (2009) · PubMed · Cited by 44
Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72
Reinbold, M., Luo, J.-L., Nedelko, T., Jerchow, B., Murphy, M. E., Whibley, C. E., Wei, Q., & Hollstein, M. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210932 · Cited by 43
Self-citationZawlik, I., Kita, D., Vaccarella, S., Mittelbronn, M. G. A., Franceschi, S., & Ohgaki, H. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00170.x · Cited by 39
Molecular precursor lesions in oesophageal cancer.
Montesano, R., & Hainaut, P. L. (1998) · PubMed · Cited by 34
Self-citationPistritto, G., Puca, R., Nardinocchi, L., Sacchi, A., & D’Orazi, G. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402186 · Cited by 30
Cancer-prone oxyradical overload disease.
Ambs, S., Hussain, S. P., Marrogi, A. J., & Harris, C. C. (1999) · PubMed · Cited by 30
Clonal Analysis of Colorectal Tumors Using K-ras and p53 Gene Mutations as Markers
Dix, B. R., Robbins, P., Spagnolo, D. V., Padovan, G. L., House, A. K., & Iacopetta, B. J. (1995) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199512000-00006 · Cited by 29
Tumor Susceptibility and Apoptosis Defect in a Mouse Strain Expressing a Human p53 Transgene
Dudgeon, C., Kek, C., Demidov, O. N., Saito, S., Fernandes, K., Diot, A., Bourdon, J., Lane, D. P., Appella, E., Fornace, A. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2063 · Cited by 25
p53 Designer Genes for the Modern Mouse
Hergenhahn, M., Luo, J., & Hollstein, M. (2004) · Cell Cycle · doi:10.4161/cc.3.6.890 · Cited by 18
Self-citationMouse models for generating P53 gene mutation spectra
Zielinski, B., Liu, Z., Hollstein, M. C., Hergenhahn, M., & Luo, J. (2002) · Toxicology Letters · doi:10.1016/s0378-4274(02)00160-1 · Cited by 5
Self-citation
Cited by
Sorted by citations
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Pan-cancer analysis of whole genomes
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature · doi:10.1038/s41586-020-1969-6 · Cited by 3,064
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype
Kumari, R., & Jat, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645593 · Cited by 1,622
Endogenous DNA damage as a source of genomic instability in cancer
Tubbs, A., & Nussenzweig, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.002 · Cited by 1,452
Metadata
- Authors
- Olivier, M., Hollstein, M., & Hainaut, P.
- Affiliations
- Centre international de recherche sur le cancer (FR)
- University of Leeds (GB)
- Venue
- Cold Spring Harbor Perspectives in Biology
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2009-11-11
- Volume
- 2
- Issue
- 1
- Pages
- a001008-a001008
- ISSN
- 1943-0264 (ISSN-L)
- PMC
- PMC2827900
- OpenAlex
- W2129769331
- Cited by
- 2,199
- References
- 118
- Citations by year
- 2026: 136 · 2025: 174 · 2024: 233 · 2023: 229 · 2022: 222 · 2021: 178 · 2020: 174 · 2019: 112 · 2018: 139 · 2017: 131 · 2016: 101 · 2015: 97 · 2014: 88 · 2013: 61 · 2012: 72
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Biology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- TP53 mutation, somatic mutations, germline TP53 mutation, Li-Fraumeni syndrome, cancer susceptibility, mutagenesis mechanism, prognostic factors, predictive biomarkers, therapeutic target, cancer etiology
- MeSH terms
- Animals, Carcinogens, Humans, Mice, Transgenic, Models, Biological, Mutation, Neoplasms, Prognosis, Gene Expression Regulation, Neoplastic, Genes, p53, Mutagenesis, CpG Islands, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
